Clairity provides an FDA-authorized AI platform that assesses future breast cancer risk using existing screening mammograms. This technology analyzes image data to generate a validated, equitable five-year risk assessment for women. The platform transforms standard diagnostic imaging into a predictive tool for early detection and prevention planning.

CryOSA is developing a medical device that employs targeted airway pressure modulation to treat obstructive sleep apnea. This non-invasive approach enhances patient compliance and minimizes the risk of health complications associated with traditional CPAP therapy.

Solu Therapeutics develops a cytotoxicity-targeting chimera platform that links bifunctional small molecules to proprietary antibodies, enabling the selective elimination of disease-driving cells in oncology and autoimmune conditions. This approach addresses the challenge of targeting previously inaccessible cell surface proteins, enhancing therapeutic efficacy while minimizing safety risks.